首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1425075

囊腫纖維化市場：預測（2024-2029）

Cystic Fibrosis Market - Forecasts from 2024 to 2029

出版日期: 2024年01月22日 | 出版商:

Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

2022 年囊腫纖維化市場價值為 9,291,199,000 美元。

產生黏液、汗水和消化液的細胞受到囊腫纖維化的影響。分泌物會堵塞而不是潤滑管道、導管和通道，尤其是在胰臟和肺部。由於囊腫纖維化的生長需要兩個不同基因的突變，因此囊腫纖維化在家族中遺傳，並且該疾病被認為是隱性遺傳的。

囊腫纖維化市場推動要素

產業對研發研究投資的增加，以及治療領域其他技術的發展，將為產業參與者創造新的成長機會。穿戴式感測器由美國國立衛生研究院的研究人員創建，用於幫助診斷和追蹤疾病的發作。該感測器可以檢測患者體內任何異常的鹽平衡，並以無線方式發送訊息進行測試。在整個預測期內，由於治療這種疾病的新治療方法和藥物開發的技術創新不斷增加，囊腫纖維化市場預計將成長。

囊腫纖維化普及不斷擴大

根據囊腫纖維化基金會 2022 年發布的最新估計，過去十年中，囊腫纖維化患者的數量增加。美國約有 40,000 名兒童和成人患有囊腫纖維化，全球估計有 105,000 人被診斷出患有囊性纖維化，這推動了囊腫纖維化市場的發展。 2012 年，美國患有 CF 的人數估計超過 30,000 人，全球患有 CF 的人數超過 70,000 人。我們使用囊腫纖維化基金會患者登記處和美國人口統計數據來計算囊性纖維化患者總數的最新估計值。

CFTR 越來越受歡迎

人體的氯離子通道、跨膜電導調節蛋白 (CFTR) 有助於控制鈉和氯離子進出肺部和其他器官的細胞膜。 CFTR 調節劑可減少肺部突發事件和呼吸道症狀，同時改善細胞體功能並改善患者的生活品質。囊腫纖維化市場的最大佔有率預計屬於 CFTR 藥物。此外，尖端治療方法的增加，包括 CFTR 調節劑的三重聯合治療，預計將推動業務發展。

來自主要企業的各種產品創新

隨著囊性纖維化治療藥物即將推出，囊腫纖維化市場正在擴大。在預期期間，針對囊性纖維化患者細胞缺陷的藥物的推出以及此類藥物改變許多人生活的潛力預計將推動囊腫纖維化市場的擴張。此外，推動囊腫纖維化市場的主要因素被認為是該疾病盛行率的不斷增加。這正在加速最近發現的治療重症患者所需的管道藥物的上市。

政府舉措增多

政府正努力為囊腫纖維化患者提供治療機會，從而增加對囊腫纖維化領域產品的需求。例如，2023 年 4 月，Trikafta（elexacaftor、tezacaftor、ivacaftor）透過藥物福利計畫（PBS）可供 6 至 11 歲囊腫纖維化患者使用。囊腫纖維化患者及其家人的生活預計將因針對該特定年齡層的 Trikafta 的推出而受到重大影響。家庭可以透過 PBS 獲得 Trikafta，每次處方箋價格高達 30 美元，6 至 11 歲兒童可透過特許經營卡獲得 7.30 美元，從而支持囊腫纖維化市場在整個預期期間的成長。

活性化市場研發

市場收益的擴張主要是由治療研發投資的增加所推動的。例如，2023年1月，旨在重塑基因療法的Gensaic公司宣布已獲得囊腫纖維化基金會的資助，用於研究該疾病的基因療法。囊腫纖維化患者數量的增加、對替代療法的需求不斷成長以及更複雜藥物的研發進展是推動囊腫纖維化市場收益成長的一些關鍵因素。

囊腫纖維化市場的臨床試驗增加

由於各種治療方法的出現，囊腫纖維化市場正在擴大。霧化抗生素給藥可減少慢性肺病患者的肺損傷並增強肺功能。阿奇黴素 FEV1 治療的隨機對照試驗表明，可減少病情加重並改善生活品質。此外，2023 年 6 月，一種革命性的囊腫纖維化新治療方法將進入臨床試驗。這種有前途的可吸入分子假體是由伊利諾大學香檳分校卡爾伊利諾醫學院和愛荷華大學卡弗醫學院的研究人員與衍生生物技術公司 Cystetic Medicines 合作開發的。其目的是改善對現有治療方法無反應的囊性纖維化患者的肺功能。

在北美，囊腫纖維化市場預計將穩定成長。

在北美地區，由於囊腫纖維化盛行率不斷上升以及該地區可用的治療方法種類繁多，囊腫纖維化市場佔有率預計將保持相當大的規模，預計將顯著擴大。透過增加用於治療囊腫纖維化的藥物研發研究的資金以及其他有益的政府舉措，將促進囊腫纖維化區域市場的擴大。囊腫纖維化社群現在可以透過北美囊腫纖維化會議 (NACFC) 提供的教育論壇討論研究和開發的最新進展。其他因素，例如囊腫纖維化市場中競爭對手的存在、先進的醫療基礎設施和醫療費用預計將刺激囊腫纖維化市場的擴張。

The cells that make mucus, perspiration, and digestive fluids are impacted by cystic fibrosis. The secretions clog up tubes, ducts, and passages rather than lubricating them, particularly in the pancreas and lungs. Cystic fibrosis runs in families because cystic fibrosis requires two different gene variations to grow, the ailment is considered to be recessive.

Driving factors for the cystic fibrosis market

Increasing industry investment in R&D research along with other technical developments in the therapeutic field creates new growth opportunities for industry participants. A wearable sensor was created by NIH researchers to aid in the diagnosis and tracking of illness development. The sensor picks up the patients' bodies' abnormal salt balance and wirelessly transmits the information for examination. Throughout the forecast period, it is predicted that the cystic fibrosis market will grow due to increased innovation in the creation of novel treatments and pharmaceutical products to treat the condition.

Growing prevalence of cystic fibrosis

According to a recent estimate by the Cystic Fibrosis Foundation published in 2022, the number of people with cystic fibrosis has grown over the previous ten years. Nearly 40,000 children and adults suffer from cystic fibrosis in the United States, while an estimated 105,000 people worldwide have received a CF diagnosis fueling the cystic fibrosis market. The number of individuals with CF was last estimated to be over 30,000 in the United States and 70,000 worldwide in 2012. The Cystic Fibrosis Foundation Patient Registry and the Vital Statistics of the United States were used to get the most recent estimate of the overall number of CF patients.

Growing popularity for CFTR

As a chloride channel in the body, the transmembrane conductance regulator (CFTR) protein aids in controlling the movement of sodium and chlorine into and out of the cell membranes of the lungs and other organs. CFTR modulators improve cellular body function and patients' quality of life while reducing lung flare-ups and respiratory symptoms. The cystic fibrosis market's largest share is anticipated to belong to CFTR medications. Additionally, the development of the business will be fueled by additional cutting-edge treatments including triple combination medications with CFTR modulators.

Various product innovations by key players

The cystic fibrosis market is expanding due to the impending launch of medications for the treatment of CF. During the anticipated period, cystic fibrosis market expansion will be aided by the introduction of medications that target the faults in diseased people's cells and the likelihood that the medications will change the lives of many people. Additionally, it is believed that growth in the disease's prevalence is the main factor driving the cystic fibrosis market. This is speeding up the launch of recently discovered pipeline drugs required for the treatment of critically ill patients.

Increase in government initiatives

Through its efforts to provide access to therapies for those who have cystic fibrosis, the government is seeking to increase demand for products in the cystic fibrosis sector. For instance, in April 2023, Trikafta (elexacaftor, tezacaftor, ivacaftor, and ivacaftor) was made available via the Pharmaceutical Benefits Scheme (PBS) for cystic fibrosis patients between the ages of 6 and 11 years old. Cystic fibrosis patients and their families' lives are anticipated to be significantly affected by the advent of Trikafta for this particular age range. Families can get Trikafta through PBS for a maximum price of $30 per prescription or $7.30 with a concession card for children aged 6 to 11, fuelling the cystic fibrosis market growth throughout the anticipated timeframe.

Rising research & development in the market

Growing market revenue is mostly being driven by rising therapeutic R&D investments. For instance, in January 2023, Gensaic, a business that wants to reinvent gene therapy, announced that it has received money from the Cystic Fibrosis Foundation to research a gene therapy for the disease. The rising frequency of cystic fibrosis patients, higher demand for alternative therapies, and ongoing research & development of more sophisticated drugs are some of the main factors propelling revenue growth in the cystic fibrosis market.

Increasing clinical trials in the cystic fibrosis market

The cystic fibrosis market is expanding as a result of a range of treatments available. Nebulized antibiotic therapy lowers lung damage and enhances lung function in patients with chronic lung disease. A randomized controlled study of azithromycin FEV1 therapy shows a decrease in exacerbations and an improvement in quality of life. Further, in June 2023, a potentially ground-breaking new therapy for cystic fibrosis is currently undergoing clinical testing. This promising inhalable molecular prosthetic was developed by researchers at the Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign and the Carver College of Medicine at the University of Iowa in collaboration with the spin-out biotechnology company, Cystetic Medicines. It aims to improve lung function in CF patients who are not responding to existing treatments.

In North America, it is projected that the cystic fibrosis market will grow steadily.

The North American region is anticipated to secure a sizable cystic fibrosis market share and is anticipated to expand significantly during the predicted period due to the rising prevalence of cystic fibrosis and the wide range of available treatments in the area. Regional cystic fibrosis market expansion will be fueled by increased financing for research and development studies on medications for cystic fibrosis and other beneficial government initiatives. The cystic fibrosis community can now discuss the most recent advancements in R&D due to educational forums offered by the North American Cystic Fibrosis Conference (NACFC). Other elements, including the existence of significant cystic fibrosis market competitors, a sophisticated healthcare infrastructure, and reimbursements, are anticipated to fuel cystic fibrosis market expansion.

Market Key Developments

In September 2022, the multi-year agreement between CytoReason and Pfizer has been extended, and Pfizer can use CytoReason's AI technology in its drug development initiatives.
In July 2022, The Cincinnati Children's Hospital Medical Centre announced a partnership with the Boomer Esiason Foundation (BEF) and the research intelligence firm Epistemic AI that will enable the division of pulmonary medicine to use artificial intelligence (AI) to speed up clinical research on cystic fibrosis and respiratory diseases.
In April 2022, The Bakar BioEnginuity Hub's incubator, Bakar Labs, and the Cystic Fibrosis Foundation jointly launched the first-ever "Golden Ticket" Competition to find the next promising cystic fibrosis drug.

Segmentation:

By Drug Class

CFTR Modulators
Mucolytics
Brochodilators
Others

By Route of Administration

Oral
Parenteral

By Distribution Channel

Hospital
Retail Pharmacies
Others

By Geography

North America
United States
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
Japan
China
India
South Korea
Indonesia
Thailand
Others

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Data
2.2. Assumptions

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Force Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis

5. CYSTIC FIBROSIS MARKET, BY DRUG CLASS

5.1. Introduction
5.2. CFTR Modulators
5.3. Mucolytics
5.4. Brochodilators
5.5. Others

6. CYSTIC FIBROSIS MARKET, BY ROUTE OF ADMINISTRATION

6.1. Introduction
6.2. Oral
6.3. Parenteral

7. CYSTIC FIBROSIS MARKET, BY DISTRIBUTION CHANNEL

7.1. Introduction
7.2. Hospital
7.3. Retail Pharmacies
7.4. Others

8. CYSTIC FIBROSIS MARKET, BY GEOGRAPHY

8.1. Introduction
8.2. North America
- 8.2.1. United States
- 8.2.2. Canada
- 8.2.3. Mexico
8.3. South America
- 8.3.1. Brazil
- 8.3.2. Argentina
- 8.3.3. Others
8.4. Europe
- 8.4.1. United Kingdom
- 8.4.2. Germany
- 8.4.3. France
- 8.4.4. Spain
- 8.4.5. Others
8.5. The Middle East and Africa
- 8.5.1. Saudi Arabia
- 8.5.2. UAE
- 8.5.3. Israel
- 8.5.4. Others
8.6. Asia Pacific
- 8.6.1. Japan
- 8.6.2. China
- 8.6.3. India
- 8.6.4. South Korea
- 8.6.5. Indonesia
- 8.6.6. Thailand
- 8.6.7. Others